mRNA Vaccine Market Projected to Reach $82.61 Billion by 2030 Amid Safety Debates
The global mRNA and next-generation vaccine platforms market is expected to grow from $39.69 billion in 2025 to $82.61 billion by 2030 at a 15.8% CAGR, driven by personalized medicine demand and infectious disease applications, while safety concerns and regulatory scrutiny continue.
The market for messenger ribonucleic acid (mRNA) and next-generation vaccine platforms is projected to increase from $39.69 billion in 2025 to $45.88 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.6%. The market is expected to reach $82.61 billion by 2030 at a CAGR of 15.8%.
The surge during this period is largely credited to breakthroughs in COVID-19 vaccines, foundational research on viral vectors, enhanced global pandemic preparedness, progress in genomic sequencing technology, and initial nucleic acid vaccine trials. Several factors will drive continued growth, including the development of personalized cancer vaccines, broadening infectious disease pipelines, faster regulatory approvals based on platform technologies, increased investment in biotech, and wider therapeutic vaccine applications.
Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms consist of cutting-edge vaccine methods that use genetic material—such as mRNA, DNA, or viral vectors—to instruct the body's immune system to produce protective proteins, thereby building immunity. Compared to traditional vaccines, these platforms offer faster development cycles, better scalability in manufacturing, enhanced adaptability to emerging infectious threats, and stronger immune responses.
A key driver propelling the mRNA and next-generation vaccine platforms market is the growing demand for personalized medicine. This medical paradigm tailors prevention and treatment strategies to an individual's unique genetic makeup, molecular traits, and health conditions. The increasing occurrence of complex and chronic diseases fuels the need for such customized therapies to improve safety and effectiveness. These vaccine platforms enable the rapid and flexible creation of highly specific vaccines and therapeutics that align with a patient's particular genetic and disease profile, supporting precision healthcare.
In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six approvals in 2022. This trend highlights the expanding role of tailored therapies, further driving the adoption and growth of mRNA and next-generation vaccine platform technologies.
Emerging trends shaping the future include self-amplifying mRNA platforms, optimization of lipid nanoparticle delivery systems, modular vaccine designs, swift adaptation to new pathogen targets, and innovative next-generation adjuvant technologies.
Scientists first discovered mRNA in 1961. A large molecule found in all of our cells, mRNA is used to make every protein that our DNA directs our bodies to build. It does so by carrying information from DNA in the nucleus out to a cell's protein-making machinery. A single mRNA molecule can be used to make many copies of a protein, but it is naturally programmed to die eventually.
In 2025, North America held the largest share of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market. However, the Asia-Pacific region is anticipated to emerge as the fastest-growing market during the forecast period.